dc.contributor.author |
Suarez-Almazor, Maria
|
|
dc.contributor.author |
Pundole, Xerxes
|
|
dc.contributor.author |
Abdel-Wahab, Noha
|
|
dc.contributor.author |
Johnson, Douglas
|
|
dc.contributor.author |
Gupta, Dipti
|
|
dc.contributor.author |
Glezerman, Ilya
|
|
dc.contributor.author |
Cooksley, Tim
|
|
dc.contributor.author |
Anderson, Ronald
|
|
dc.contributor.author |
Blidner, Ada Gabriela
|
|
dc.contributor.author |
Choi, Jennifer
|
|
dc.contributor.author |
Dougan, Michael
|
|
dc.contributor.author |
Ginex, Pamela
|
|
dc.contributor.author |
Girotra, Monica
|
|
dc.contributor.author |
Shannon, Vickie R.
|
|
dc.contributor.author |
Rapoport, Bernardo Leon
|
|
dc.date.accessioned |
2020-10-26T11:51:41Z |
|
dc.date.issued |
2020-12 |
|
dc.description.abstract |
Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents. |
en_ZA |
dc.description.department |
Immunology |
en_ZA |
dc.description.embargo |
2021-08-20 |
|
dc.description.librarian |
hj2020 |
en_ZA |
dc.description.sponsorship |
The Cancer Association of South Africa (CANSA), the National Research Foundation (NRF) of South Africa and the NIH/NCI (Cancer Center Support Grant P30 CA008748). |
en_ZA |
dc.description.uri |
http://link.springer.com/journal/520 |
en_ZA |
dc.identifier.citation |
Suarez-Almazor, M.E., Pundole, X., Abdel-Wahab, N. et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Support Care in Cancer 28, 6159–6173 (2020). https://doi.org/10.1007/s00520-020-05710-8. |
en_ZA |
dc.identifier.issn |
0941-4355 (print) |
|
dc.identifier.issn |
1433-7339 (online) |
|
dc.identifier.other |
10.1007/s00520-020-05710-8 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/76607 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Springer |
en_ZA |
dc.rights |
© Springer-Verlag GmbH Germany, part of Springer Nature 2020. The original publication is available at : http://link.springer.com/journal/520. |
en_ZA |
dc.subject |
Arthralgia |
en_ZA |
dc.subject |
Immune checkpoint inhibitor (ICI) |
en_ZA |
dc.subject |
Arthritis |
en_ZA |
dc.subject |
Cardiomyopathy |
en_ZA |
dc.subject |
Corticosteroids |
en_ZA |
dc.subject |
Myocarditis |
en_ZA |
dc.subject |
Myositis |
en_ZA |
dc.subject |
Immunomodulation agents |
en_ZA |
dc.subject |
Other immunosuppressive agents |
en_ZA |
dc.subject |
Polymyalgia |
en_ZA |
dc.title |
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors |
en_ZA |
dc.type |
Postprint Article |
en_ZA |